MOTIVATION LETTER The Conjunctive Consolidation Threshold model predicts an 85.8 percent reduction in reward-memory encoding probability through a tripartite pharmacological intervention. This result, validated by ODE/RK45 numerical integration and Bayesian MCMC across five pre-registered hypotheses, represents a paradigm shift in addiction neuroscience. I submit this work to the CIFAR Azrieli Global Scholars Program because CIFAR explicitly funds interdisciplinary, high-risk research that challenges disciplinary boundaries. My CCT framework merges computational neuroscience, Bayesian statistics, and clinical pharmacology into a single falsifiable architecture. CIFAR's mission to connect researchers across fields aligns with my trajectory. I built IMPRINT, an addiction-liability screening platform; TOPOLOGIX, a topological data analysis tool for drug-protein interactions using persistent homology and bipartite simplicial complexes; and GATE, a BCI neural-stimulation safety evaluation suite released under Apache 2.0. These platforms demonstrate PI-level leadership and technical breadth. My endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm that established leaders in computational neuroscience and reward learning recognize the CCT model's significance. I hold a B.Pharm from the University of Ibadan with a German-equivalent grade of 1.9 and a PCN pharmacist license. I have three sole-authored preprints on OSF and Zenodo, a review article under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper under review at Alcohol. I filed a provisional patent on the CCT core architecture in Q3 2026. My independent research at ZYCO in Lagos, Nigeria, produced all of this without a PhD or faculty appointment. I acknowledge that the CIFAR Azrieli Global Scholars Program requires a PhD and a full-time faculty position. I am not enrolled in a PhD program; I will apply for an MSc starting October 2026 at MUG in Graz, Austria. However, my independent research record, sole-authored preprints, patent, and endorsements constitute an equivalent to a first independent position. I request a waiver of the PhD requirement based on documented evidence of PI-level output. The CCT model is ready for multi-site validation, and CIFAR's network of global scholars is the ideal environment to scale this work from a single-researcher framework to a collaborative clinical trial program. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a fundamental gap in addiction neuroscience: no existing pharmacological intervention prevents the encoding of reward-associated memories during the consolidation window. Current treatments target dopamine receptors, opioid receptors, or glutamate systems individually, achieving at best partial efficacy. The CCT model specifies that three concurrent mechanisms must operate above a conjunctive threshold to block memory consolidation: D1 receptor antagonism, mu-opioid receptor antagonism, and NMDA receptor partial agonism. Below this threshold, any single intervention fails. My formal mathematical specification, published on OSF, defines the CCT as a system of ordinary differential equations governing the temporal dynamics of cAMP response element-binding protein phosphorylation, immediate early gene expression, and synaptic plasticity markers. Numerical integration using RK45 with adaptive step sizing shows that the tripartite intervention reduces encoding probability from 0.855 to 0.122, an 85.8 percent reduction. Bayesian MCMC estimation of population-level parameters confirms super-additivity of 12.8 percentage points beyond the sum of individual effects. All five pre-registered hypotheses H1 through H5 were confirmed. The clinical trial architecture, detailed in my Zenodo preprint, proposes a three-arm, double-blind, randomized controlled trial with 240 participants across four sites in Nigeria and South Africa. The primary endpoint is cue-induced craving at 72 hours post-intervention, measured by the Obsessive Compulsive Drinking Scale. Secondary endpoints include fMRI BOLD response in the nucleus accumbens and dorsolateral prefrontal cortex during cue exposure, and relapse rates at 30 and 90 days. Bayesian adaptive randomization with a 1:1:1 allocation ratio and interim analyses at 40 and 80 participants per arm minimizes sample size while maintaining statistical power at 0.90. CIFAR's emphasis on interdisciplinary collaboration is critical for this work. The CCT model requires expertise in computational neuroscience for the mathematical framework, pharmacology for the drug selection and dosing, Bayesian statistics for the trial design, and clinical addiction medicine for the patient population. I have built the computational and pharmacological components independently. CIFAR would provide the clinical and statistical collaborators needed to move from simulation to human trials. SHORT ESSAY: LEADERSHIP AND INDEPENDENCE I lead independent research at ZYCO in Lagos, Nigeria, without a PhD or faculty appointment. This is not a postdoctoral position; I define the research agenda, secure funding through competitive grants and contracts, supervise two junior researchers, and publish sole-authored preprints. My provisional patent on the CCT core architecture, filed Q3 2026, is held in my name. I built three software platforms from conception to deployment: IMPRINT for addiction-liability screening, TOPOLOGIX for topological drug-protein interaction analysis, and GATE for BCI safety evaluation. Each platform required independent decision-making on architecture, validation, and licensing. My endorsements from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar reflect their assessment that my work meets the standard of an independent principal investigator. Gershman endorsed my arXiv submission. Berridge reviewed the CCT framework and provided feedback on the dopamine component. Daw and Mattar discussed the Bayesian trial architecture. These are not casual references; they are substantive engagements with my research program. CIFAR selects scholars who demonstrate leadership potential and the ability to direct a research group. I have done exactly that without institutional support. A CIFAR Azrieli Global Scholarship would formalize my independent status, connect me to a global network of senior researchers, and provide the resources to launch the multi-site clinical trial that the CCT model requires. SHORT ESSAY: INTERDISCIPLINARY FIT WITH CIFAR The CCT model is inherently interdisciplinary. It draws on computational neuroscience for the mathematical framework, pharmacology for the drug mechanisms, Bayesian statistics for the trial design, and clinical addiction medicine for the patient population. CIFAR's research programs explicitly fund work that crosses disciplinary boundaries, and the Neuropharm track is a direct fit. My platforms demonstrate this interdisciplinary approach. TOPOLOGIX uses topological data analysis, specifically persistent homology on bipartite simplicial complexes, to predict drug-protein interactions. This merges algebraic topology with computational pharmacology. GATE evaluates BCI neural-stimulation safety by combining electrophysiology models with pharmacokinetic simulations. IMPRINT screens addiction liability using machine learning on molecular descriptors and behavioral data. CIFAR's community model, where scholars meet two to three times per year for intensive cross-disciplinary discussion, is the ideal environment for the CCT model. The framework needs input from clinical trialists, neuroethicists, and regulatory scientists to move from simulation to human testing. CIFAR provides that network. I am fluent in English, hold a valid Nigerian passport, and am available for the virtual interview on March 24-26, 2026. CHECKLIST - [ ] Motivation letter, 300-500 words, tailored to CIFAR Azrieli Global Scholars Program - [ ] Research statement, 400-600 words, detailing CCT model, validation, and clinical trial architecture - [ ] Short essay on leadership and independence, 200-350 words - [ ] Short essay on interdisciplinary fit with CIFAR, 200-350 words - [ ] CV with ORCID, GitHub, ZYCO affiliation, publications, patents, and platforms - [ ] Two reference letters from endorsers (Berridge, Gershman, Daw, or Mattar) - [ ] Provisional patent documentation for CCT core architecture - [ ] Preprint links: OSF 10.17605/OSF.IO/KG7B5, OSF 10.17605/OSF.IO/EMY4U, Zenodo 10.5281/zenodo.20492472 - [ ] Proof of PCN pharmacist license - [ ] Valid passport copy - [ ] Statement requesting PhD requirement waiver, with evidence of PI-level independent research EDITOR NOTES - Eligibility is the critical risk. The program explicitly requires a PhD and a full-time faculty position. Eniola must submit a formal waiver request with documented evidence of independent research output, endorsements, and patent. Without a waiver, the application will be rejected at screening. - The application deadline is January 1, 2026. Eniola must confirm that the provisional patent was filed before this date. The profile states Q3 2026, which is after the deadline. Verify the filing date and adjust the timeline if needed. - Eniola's age is 29, and the program targets junior faculty who started their first independent position post-PhD no earlier than July 2021. Eniola has no PhD, so this criterion cannot be met. The waiver argument must address this directly. - The virtual interview dates are March 24-26, 2026. Eniola must confirm availability and ensure internet connectivity in Lagos is reliable for a video interview. - The program requires a secure position from April 1, 2026 to March 31, 2028. Eniola's current role as National Product Manager at Synthcare is a commercial position, not a research faculty appointment. Clarify whether ZYCO can provide a letter confirming a research position with PI responsibilities for this period.